1. Home
  2. Stocks
  3. Panaceabio Share Price

Panacea Biotec Share Price

Pharmaceuticals Small Cap

₹377.10 +17.95 (5%)

05 Nov, 2024 17:26

SIP TrendupStart SIP in PANACEABIO

Start SIP
Performance Financial Technical Events FnO Shareholding Pattern More FAQ’s

Performance

  • Low
  • ₹362
  • High
  • ₹377
  • 52 Week Low
  • ₹112
  • 52 Week High
  • ₹377
  • Open Price₹365
  • Previous Close₹359
  • Volume166,395

Investment Returns

  • Over 1 Month + 22.75%
  • Over 3 Month + 171.76%
  • Over 6 Month + 169.07%
  • Over 1 Year + 144.08%
SIP Lightning

Smart Investing Starts Here Start SIP with Panacea Biotec for Steady Growth!

Panacea Biotec Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -83.3
  • PEG Ratio
  • 0.5
  • Market Cap Cr
  • 2,310
  • P/B Ratio
  • 2.8
  • Average True Range
  • 19.58
  • EPS
  • 0.6
  • Dividend Yield
  • 0
  • MACD Signal
  • 9.23
  • RSI
  • 65.42
  • MFI
  • 58.85

Panacea Biotec Financial

IndicatorJun 24Mar 24Dec 23Sep 23Jun 23
Net Sales/Income from operations56.8880.3795.2394.5989.41
Total Income From Operations56.8880.3795.2394.5989.41
P/L Before Interest, Excpt. Items & Tax-11.772.014.486.754.75
P/L Before Exceptional Items & Tax-14.98-1.351.073.201.29
P/L After Tax from Ordinary Activities-13.78-1.370.433.201.29
Net Profit/Loss For the Period-13.78-1.370.433.201.29
IndicatorMar 24Mar 23
Revenue From Operations [Gross]359.60255.96
Revenue From Operations [Net]359.60255.96
Total Operating Revenues359.60257.07
Total Revenue384.51291.50
Total Expenses380.30354.25
Profit/Loss Before Tax4.21-62.75
Profit/Loss For The Period3.55-87.54
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity37.27-10.74
Net Cash Used In Investing Activity-51.012.41
Net Cash Used in Finance Activity12.829.01
Net Inc/Dec In Cash And Equivalent-0.920.67
Cash And Equivalent End Of Year5.096.01
IndicatorMar 24Mar 23
Total Share Capital6.1311.11
Total Non-Current Liabilities175.51140.32
Total Current Liabilities248.98252.95
Total Capital And Liabilities753.64723.90
Total Non-Current Assets570.44518.77
Total Current Assets183.20205.13
Total Assets753.64723.90
Indicator20242023
EBIT Margin (%)5.00-20.49
Return On Capital Employed (%)3.56-11.18
Return On Equity (%)1.07-28.79
Long Term Debt To Equity (%)37.9332.04
Book Value/Share (INR)53.6949.63
IndicatorJun 24Mar 24Dec 23Sep 23Jun 23
Net Sales/Income from operations115.72136.46150.50143.02129.19
Total Income From Operations115.72136.46150.50143.02129.19
P/L Before Interest, Excpt. Items & Tax-18.92-4.04-3.58-9.64-13.71
P/L Before Exceptional Items & Tax-19.79-4.86-4.43-10.55-14.71
P/L After Tax from Ordinary Activities-15.88-1.99-2.20-8.2910.98
Net Profit/Loss For the Period-15.88-1.99-2.20-8.2910.98
IndicatorMar 24Mar 23
Revenue From Operations [Gross]559.17456.92
Revenue From Operations [Net]559.17456.92
Total Operating Revenues559.17459.95
Total Revenue584.97511.61
Total Expenses619.52601.47
Profit/Loss Before Tax1.4812.81
Profit/Loss For The Period-1.50-33.75
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity-0.10-422.45
Net Cash Used In Investing Activity10.23430.33
Net Cash Used in Finance Activity-2.81-18.37
Net Inc/Dec In Cash And Equivalent7.32-10.50
Cash And Equivalent End Of Year47.1739.85
IndicatorMar 24Mar 23
Total Share Capital6.1311.11
Total Non-Current Liabilities93.6294.24
Total Current Liabilities308.83331.83
Total Capital And Liabilities1,240.681,271.17
Total Non-Current Assets755.51702.85
Total Current Assets485.17568.32
Total Assets1,240.681,271.17
Indicator20242023
EBIT Margin (%)-5.53-18.57
Return On Capital Employed (%)-3.32-9.09
Return On Equity (%)-0.13-4.04
Long Term Debt To Equity (%)2.491.84
Book Value/Share (INR)136.74133.63

Panacea Biotec Technicals

EMA & SMA

Current Price
₹377.10
+ 17.95 (5%)
pointer
  • stock-down_img
  • Bullish Moving Average 16
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹317.44
  • 50 Day
  • ₹287.39
  • 100 Day
  • ₹245.54
  • 200 Day
  • ₹206.50

Resistance and Support

350.55 Pivot Speed
  • R3 402.10
  • R2 382.05
  • R1 370.60
  • S1 339.10
  • S2 319.05
  • S3 307.60

Is Panacea Biotec Worth Buying?

BUY SELL HOLD

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Panacea Biotec is a biotechnology company specializing in research, development, and manufacturing of vaccines, pharmaceuticals, and biosimilars. It operates state-of-the-art facilities in India, serving global markets across North America, Europe, and emerging economies. Panacea Biotec (Nse) has an operating revenue of Rs. 545.70 Cr. on a trailing 12-month basis. An annual revenue growth of 14% is good, Pre-tax margin of 0% needs improvement, ROE of -0% is poor and needs improvement. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 14% and 83% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 0% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 15 which is a POOR score indicating inconsistency in earnings, a RS Rating of 95 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 32 indicates it belongs to a strong industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail. Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation. (+)

Panacea Biotec Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-13 Quarterly Results
2024-08-14 Quarterly Results
2024-05-30 Audited Results
2024-02-13 Quarterly Results
2023-11-10 Quarterly Results

Panacea Biotec F&O

Panacea Biotec Shareholding Pattern

73.46%
0%
0.26%
20.42%
5.86%
  • NSE Symbol
  • PANACEABIO
  • BSE Symbol
  • 531349
  • Chairman & Managing Director
  • Dr. Rajesh Jain
  • ISIN
  • INE922B01023

Panacea Biotec FAQs

Panacea Biotec share price is ₹377 As on 05 November, 2024 | 17:12

The Market Cap of Panacea Biotec is ₹2309.8 Cr As on 05 November, 2024 | 17:12

The P/E ratio of Panacea Biotec is -83.3 As on 05 November, 2024 | 17:12

The PB ratio of Panacea Biotec is 2.8 As on 05 November, 2024 | 17:12

Q2FY23
Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

The Vigilance Awareness Week for the year 2024 (VAW 2024) would be observed from October 28, 2024 to November 03, 2024
“सत्यनिष्ठा की संस्कृनि सेराष्र की समद्ृधि” “Culture of Integrity for Nation's Prosperity”
e-pledge link (https://pledge.cvc.nic.in/)

5paisa Capital Ltd. CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 30/07/2027 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

*Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of ₹10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

Contact Us

Attention Investors

  • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
  • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
  • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

Email: support@5paisa.com

Support Desk Helpline: 8976689766

©2024, 5paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.